[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Qualigen Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":122},{"warningLetters":4,"total":121},[5,34,57,79,99],{"id":6,"raw":7,"subject":15,"body_html":16,"body_text":17,"firm_name":18,"letter_id":19,"created_at":20,"fei_number":21,"letter_url":22,"updated_at":23,"action_type":24,"case_status":25,"posted_date":26,"marcs_cms_no":27,"product_type":28,"closeout_date":29,"issuing_office":11,"recipient_name":30,"body_fetched_at":31,"delivery_method":32,"recipient_title":21,"reference_number":21,"action_taken_date":33,"medical_device_id":21,"response_letter_date":21},1253,[8,9,10,11,12,13,14,13],"\u003Ctime datetime=\"2024-09-17T13:20:00Z\">09\u002F17\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-09-11T04:00:00Z\">09\u002F11\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fquality-cdmo-inc-665961-09112024\">Quality CDMO, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unapproved New Drugs\u003Cbr \u002F>\r\n","","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fquality-cdmo-inc-665961-05012026-0\">\u003Ctime datetime=\"2026-05-11T04:00:00Z\">05\u002F11\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","Unapproved New Drugs","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Anin Shakiba\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Quality CDMO, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5000 South Freeway, Suite 106\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fort Worth\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76115\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:a.shakiba@qcdmo.com\"> a.shakiba@qcdmo.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 11, 2024\u003Cbr>\n\u003Cbr>\nRE: CMS 665961\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Shakiba:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration inspected your drug manufacturing facility, Quality CDMO, Inc. FEI 3017569510, at 5000 South Freeway, Suite 106, Fort Worth, TX, from June 12 – 16, 2023. Based on our inspection and subsequent review of your firm’s website, we found violations of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act).\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures many drug products, including Sodium Sulfacetamide 10% Wash, Sodium Sulfacetamide 10% and Sulfur 5% Cleanser, Selenium Sulfide 2.25% Shampoo, Urea 40% Cream, and Salicylic Acid 5.9% Topical Cream as prescription drug products. Your firm is responsible for introducing or delivering for introduction into interstate commerce products that are unapproved new drugs under section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). Introducing, or delivering unapproved new drug products for introduction into interstate commerce is prohibited under sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C., 331(d) and 355(a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Sodium Sulfacetamide 10% Wash, Sodium Sulfacetamide 10% and Sulfur 5% Cleanser, Selenium Sulfide 2.25% Shampoo, Urea 40% Cream, and Salicylic Acid 5.9% Topical Cream are drugs as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>We reviewed labeling collected at your firm and labeling submitted to the electronic Drug Registration and Listing System for the products listed above that provide evidence of the intended uses (as defined in 21 CFR 201.128) of your products, which include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>Sodium Sulfacetamide 10% Wash\u003Cbr>\n• Indicated for “topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). It also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides.”\u003C\u002Fp>\n\n\u003Cp>Sodium Sulfacetamide 10% and Sulfur 5% Cleanser\u003Cbr>\n• Indicated for use in “the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.”\u003C\u002Fp>\n\n\u003Cp>Selenium Sulfide 2.25% Shampoo\u003Cbr>\n• Indicated for the treatment of “seborrheic dermatitis of the scalp, dandruff and tinea versicolor.”\u003C\u002Fp>\n\n\u003Cp>Urea 40% Cream\u003Cbr>\n• Indicated for “the treatment of hyperkeratotic conditions such as dry, rough skin, xerosis, ichthyosis, skin cracks and fissures, dermatitis, eczema, psoriasis, keratoses and calluses.”\u003C\u002Fp>\n\n\u003Cp>Salicylic Acid 5.9% topical cream\u003Cbr>\n• Indicated as a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders, including verrucae and the various ichthyoses, keratosis palmaris and plantaris, keratosis pilaris, pityriasis rubra pilaris, and psoriasis.\u003C\u002Fp>\n\n\u003Cp>Your products, Sodium Sulfacetamide 10% Wash, Sodium Sulfacetamide 10% and Sulfur 5% Cleanser, Selenium Sulfide 2.25% Shampoo, Urea 40% Cream, and Salicylic Acid 5.9% Topical Cream are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, are considered new drugs as defined in section 201(p)(1) of the FD&amp;C Act. Subject to certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). Because no FDA-approved applications are in effect for your products pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, the introduction or delivery for introduction of these products into interstate commerce violates section 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist in connection with your products. You are responsible for investigating and determining the causes of violations identified above and for preventing their recurrence and the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct the violations cited in this letter. Failure to promptly correct these violations may result in legal actions without further notice, including, without limitation, seizure and injunction. Other federal agencies may take this Warning Letter into account when considering the award of contracts. You should discontinue marketing all of the unapproved prescription drugs manufactured at your facility immediately. Additionally, FDA may withhold approval of requests for export certificates or approval of pending new drug applications listing your facility as a manufacturer until the above violations are corrected. A reinspection may be necessary to verify corrective actions have been completed.\u003C\u002Fp>\n\n\u003Cp>FDA requests that you contact CDER's Drug Shortages Staff immediately at drugshortages@fda.hhs.gov so that we can work with you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture, as required under 21 U.S.C.§ 356c(a), and to allow FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who use your products.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen (15) working days of receiving this letter of the steps you have taken to bring your firm into compliance with the law. Your response should include each step that has been taken or will be taken to correct the violations and prevent their recurrence. If the corrective action cannot be completed within fifteen (15) working days of receiving this letter, state the reason for the delay and the timeframe within which the corrections will be completed. Please include copies of any documentation demonstrating that corrections have been made. If you no longer manufacture or market the above-mentioned products, or any other unapproved new drug products that you have listed in the FDA electronic Drug Registration and Listing System (eDRLS), your response should indicate this, including the reasons that, and the date on which, you ceased production. Also, please indicate your progress in updating the drug listing eDRLS files in accordance with 21 CFR 207.30(a)(2). If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration within 15 working days.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “CMS 665961” in the subject line of the email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Tina Smith, M.S.\u003Cbr>\nCaptain, U.S. Public Health Service\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nAnin Shakiba\n\nRecipient Title\n\nPresident\n\nQuality CDMO, Inc.\n\n5000 South Freeway, Suite 106\n\nFort Worth, TX 76115\n\nUnited States\n\na.shakiba@qcdmo.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\n\nSeptember 11, 2024\n\nRE: CMS 665961\n\nDear Mr. Shakiba:\n\nThe U.S. Food and Drug Administration inspected your drug manufacturing facility, Quality CDMO, Inc. FEI 3017569510, at 5000 South Freeway, Suite 106, Fort Worth, TX, from June 12 – 16, 2023. Based on our inspection and subsequent review of your firm’s website, we found violations of the Federal Food, Drug, and Cosmetic Act (the FD&C Act).\n\nYour firm manufactures many drug products, including Sodium Sulfacetamide 10% Wash, Sodium Sulfacetamide 10% and Sulfur 5% Cleanser, Selenium Sulfide 2.25% Shampoo, Urea 40% Cream, and Salicylic Acid 5.9% Topical Cream as prescription drug products. Your firm is responsible for introducing or delivering for introduction into interstate commerce products that are unapproved new drugs under section 505(a) of the FD&C Act, 21 U.S.C. 355(a). Introducing, or delivering unapproved new drug products for introduction into interstate commerce is prohibited under sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C., 331(d) and 355(a). These violations are described in more detail below.\n\nUnapproved New Drug Violations\n\nSodium Sulfacetamide 10% Wash, Sodium Sulfacetamide 10% and Sulfur 5% Cleanser, Selenium Sulfide 2.25% Shampoo, Urea 40% Cream, and Salicylic Acid 5.9% Topical Cream are drugs as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\n\nWe reviewed labeling collected at your firm and labeling submitted to the electronic Drug Registration and Listing System for the products listed above that provide evidence of the intended uses (as defined in 21 CFR 201.128) of your products, which include, but may not be limited to, the following:\n\nSodium Sulfacetamide 10% Wash\n\n• Indicated for “topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). It also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides.”\n\nSodium Sulfacetamide 10% and Sulfur 5% Cleanser\n\n• Indicated for use in “the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.”\n\nSelenium Sulfide 2.25% Shampoo\n\n• Indicated for the treatment of “seborrheic dermatitis of the scalp, dandruff and tinea versicolor.”\n\nUrea 40% Cream\n\n• Indicated for “the treatment of hyperkeratotic conditions such as dry, rough skin, xerosis, ichthyosis, skin cracks and fissures, dermatitis, eczema, psoriasis, keratoses and calluses.”\n\nSalicylic Acid 5.9% topical cream\n\n• Indicated as a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders, including verrucae and the various ichthyoses, keratosis palmaris and plantaris, keratosis pilaris, pityriasis rubra pilaris, and psoriasis.\n\nYour products, Sodium Sulfacetamide 10% Wash, Sodium Sulfacetamide 10% and Sulfur 5% Cleanser, Selenium Sulfide 2.25% Shampoo, Urea 40% Cream, and Salicylic Acid 5.9% Topical Cream are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, are considered new drugs as defined in section 201(p)(1) of the FD&C Act. Subject to certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). Because no FDA-approved applications are in effect for your products pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, the introduction or delivery for introduction of these products into interstate commerce violates section 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist in connection with your products. You are responsible for investigating and determining the causes of violations identified above and for preventing their recurrence and the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\n\nYou should take prompt action to correct the violations cited in this letter. Failure to promptly correct these violations may result in legal actions without further notice, including, without limitation, seizure and injunction. Other federal agencies may take this Warning Letter into account when considering the award of contracts. You should discontinue marketing all of the unapproved prescription drugs manufactured at your facility immediately. Additionally, FDA may withhold approval of requests for export certificates or approval of pending new drug applications listing your facility as a manufacturer until the above violations are corrected. A reinspection may be necessary to verify corrective actions have been completed.\n\nFDA requests that you contact CDER's Drug Shortages Staff immediately at drugshortages@fda.hhs.gov so that we can work with you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture, as required under 21 U.S.C.§ 356c(a), and to allow FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who use your products.\n\nPlease notify this office in writing within fifteen (15) working days of receiving this letter of the steps you have taken to bring your firm into compliance with the law. Your response should include each step that has been taken or will be taken to correct the violations and prevent their recurrence. If the corrective action cannot be completed within fifteen (15) working days of receiving this letter, state the reason for the delay and the timeframe within which the corrections will be completed. Please include copies of any documentation demonstrating that corrections have been made. If you no longer manufacture or market the above-mentioned products, or any other unapproved new drug products that you have listed in the FDA electronic Drug Registration and Listing System (eDRLS), your response should indicate this, including the reasons that, and the date on which, you ceased production. Also, please indicate your progress in updating the drug listing eDRLS files in accordance with 21 CFR 207.30(a)(2). If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration within 15 working days.\n\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “CMS 665961” in the subject line of the email.\n\nSincerely,\n\n\u002FS\u002F\n\nTina Smith, M.S.\n\nCaptain, U.S. Public Health Service\n\nDirector\n\nOffice of Unapproved Drugs & Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration","Quality CDMO, Inc.","quality-cdmo-inc-665961-09112024","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fquality-cdmo-inc-665961-09112024","2026-10-26T08:09:46.109501+00:00","Warning Letter","Closed Out","2024-09-17","665961","Drugs","2026-05-11","Anin Shakiba","2026-08-19T23:47:50.316+00:00","Via Email","2024-09-11",{"id":35,"raw":36,"subject":41,"body_html":42,"body_text":43,"firm_name":44,"letter_id":45,"created_at":46,"fei_number":21,"letter_url":47,"updated_at":48,"action_type":24,"case_status":49,"posted_date":50,"marcs_cms_no":51,"product_type":52,"closeout_date":21,"issuing_office":40,"recipient_name":53,"body_fetched_at":54,"delivery_method":55,"recipient_title":21,"reference_number":21,"action_taken_date":56,"medical_device_id":21,"response_letter_date":21},2230,[37,38,39,40,41,13,13,13],"\u003Ctime datetime=\"2023-01-31T14:20:00Z\">01\u002F31\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-06-01T04:00:00Z\">06\u002F01\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fss-quality-wholesale-inc-630772-06012022\">S&amp;S Quality Wholesale Inc.\u003C\u002Fa>","Division of Southwest Imports","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Gali Sleman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>S&amp;S Quality Wholesale Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1200 Billy Mitchell Dr. Ste. E\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>El Cajon\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92020-1135\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ssqualitywholesale@yahoo.com\"> ssqualitywholesale@yahoo.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Southwest Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 1, 2022\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 630772\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Sleman,\u003C\u002Fp>\n\n\u003Cp>On February 14, 2022, through February 16, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of S&amp;S Quality Wholesale Inc. located at 1200 Billy Mitchell Dr. Ste. E, El Cajon, CA 92020-1135. We also conducted an inspection on April 16, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\"> https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the food products you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a, FSVP Observations.\u003C\u002Fp>\n\n\u003Cp>We have not received your response to the Form FDA 483a issued on February 16, 2022.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR part 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Bashan Koftelik Bulgur Fine imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Bread Sticks imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Wheat Kernal Habiya imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the foods you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert #99-41 at: \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, Attention: CDR Toby H. Hill, Compliance Officer, Division of Southwest Imports, One Main Place, 1201 Main Street, Suite 7200, Dallas, TX 75202. If you have any questions regarding this letter, you may contact Compliance Officer CDR Toby H. Hill via email at toby.hill@fda.hhs.gov. Please reference CMS # 630772 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Todd Cato\u003Cbr>\nDivision of Southwest Imports Director\u003Cbr>\nOne Main Place\u003Cbr>\n1201 Main Street, Suite 7200\u003Cbr>\nDallas, TX 75202\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Gali Sleman\n\nRecipient Title\n\nOwner\n\nS&S Quality Wholesale Inc.\n\n1200 Billy Mitchell Dr. Ste. E\n\nEl Cajon, CA 92020-1135\n\nUnited States\n\nssqualitywholesale@yahoo.com\n\nIssuing Office:\n\nDivision of Southwest Imports\n\nUnited States\n\nWARNING LETTER\n\nJune 1, 2022\n\nRe: CMS # 630772\n\nDear Mr. Sleman,\n\nOn February 14, 2022, through February 16, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of S&S Quality Wholesale Inc. located at 1200 Billy Mitchell Dr. Ste. E, El Cajon, CA 92020-1135. We also conducted an inspection on April 16, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the food products you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a, FSVP Observations.\n\nWe have not received your response to the Form FDA 483a issued on February 16, 2022.\n\nYour significant violations of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR part 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including:\n\nBashan Koftelik Bulgur Fine imported from (b)(4), located in (b)(4)\n\nBread Sticks imported from (b)(4), located in (b)(4)\n\nWheat Kernal Habiya imported from (b)(4), located in (b)(4)\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the foods you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert #99-41 at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to the Food and Drug Administration, Attention: CDR Toby H. Hill, Compliance Officer, Division of Southwest Imports, One Main Place, 1201 Main Street, Suite 7200, Dallas, TX 75202. If you have any questions regarding this letter, you may contact Compliance Officer CDR Toby H. Hill via email at toby.hill@fda.hhs.gov. Please reference CMS # 630772 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nTodd Cato\n\nDivision of Southwest Imports Director\n\nOne Main Place\n\n1201 Main Street, Suite 7200\n\nDallas, TX 75202","S&S Quality Wholesale Inc.","ss-quality-wholesale-inc-630772-06012022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fss-quality-wholesale-inc-630772-06012022","2026-10-26T08:10:03.281049+00:00","Issued","2023-01-31","630772","Food & Beverages","Mr. Gali Sleman","2026-08-20T01:17:37.064+00:00","Via Express Delivery","2022-06-01",{"id":58,"raw":59,"subject":64,"body_html":65,"body_text":66,"firm_name":67,"letter_id":68,"created_at":69,"fei_number":21,"letter_url":70,"updated_at":71,"action_type":24,"case_status":49,"posted_date":72,"marcs_cms_no":73,"product_type":74,"closeout_date":21,"issuing_office":63,"recipient_name":21,"body_fetched_at":75,"delivery_method":76,"recipient_title":21,"reference_number":77,"action_taken_date":78,"medical_device_id":21,"response_letter_date":21},522,[60,61,62,63,64,13,13,13],"\u003Ctime datetime=\"2025-10-28T04:00:00Z\">10\u002F28\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-23T04:00:00Z\">10\u002F23\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fquality-wholesale-stl-llc-717169-10232025\">Quality Wholesale STL, LLC \u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2501313\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Quality Wholesale STL, LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2059 Concourse Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Louis\u003C\u002Fspan>, \u003Cspan>MO\u003C\u002Fspan> \u003Cspan>63146\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 23, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Quality Wholesale STL, LLC sells and\u002For distributes electronic nicotine delivery system (ENDS) products to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order, including: YOVO STARWALK WATERMELON ICE 5% 20ml.\u003C\u002Fp>\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, ER2501313, in your response and direct your response to the following address:\u003C\u002Fp>\u003Cp>DEM-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2501313\n\nProduct:\n\nTobacco\n\nRecipient:\n\nQuality Wholesale STL, LLC\n\n2059 Concourse Drive\n\nSaint Louis, MO 63146\n\nUnited States\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nOctober 23, 2025\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Quality Wholesale STL, LLC sells and\u002For distributes electronic nicotine delivery system (ENDS) products to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order, including: YOVO STARWALK WATERMELON ICE 5% 20ml.\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act.\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, ER2501313, in your response and direct your response to the following address:\nDEM-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products","Quality Wholesale STL, LLC","quality-wholesale-stl-llc-717169-10232025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fquality-wholesale-stl-llc-717169-10232025","2026-10-26T08:09:46.181569+00:00","2025-10-28","717169","Tobacco","2026-08-19T16:12:33.688+00:00","VIA UPS and Electronic Mail","ER2501313","2025-10-23",{"id":80,"raw":81,"subject":86,"body_html":87,"body_text":88,"firm_name":89,"letter_id":90,"created_at":20,"fei_number":21,"letter_url":91,"updated_at":92,"action_type":24,"case_status":49,"posted_date":93,"marcs_cms_no":94,"product_type":52,"closeout_date":21,"issuing_office":85,"recipient_name":95,"body_fetched_at":96,"delivery_method":97,"recipient_title":21,"reference_number":21,"action_taken_date":98,"medical_device_id":21,"response_letter_date":21},1330,[82,83,84,85,86,13,13,13],"\u003Ctime datetime=\"2024-08-06T13:20:00Z\">08\u002F06\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-07-08T04:00:00Z\">07\u002F08\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhigh-quality-organics-inc-677503-07082024\">High Quality Organics, Inc.\u003C\u002Fa>","Division of Human and Animal Food Operations West V","CGMP\u002FFood\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Boligala C. Raju\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>High Quality Organics, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>12101 Moya Blvd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Reno\u003C\u002Fspan>, \u003Cspan>NV\u003C\u002Fspan> \u003Cspan>89506-2600\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations West V\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 8, 2024\u003C\u002Fp>\n\n\u003Cp>WL CMS# 677503\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Raju:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your ready-to-eat (RTE) spice facility, located at 12101 Moya Blvd., Reno, NV, from November 27 through December 07, 2023, and January 03 through January 04, 2024. The inspection covered processing and\u002For packaging of RTE organic herbs, spices, dried fruit and peels, and dried vegetables. During our inspection, FDA investigators found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117).\u003C\u002Fp>\n\n\u003Cp>Based on FDA’s inspectional findings, we have determined that the RTE herbs, spices, dried fruit and peels, and dried vegetables processed and\u002For packaged in your facility are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)] in that they have been prepared, packed or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP &amp; PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about the CGMP &amp; PC rule through links on FDA’s homepage at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, FDA investigators issued a Form FDA 483 (FDA-483), Inspectional Observations. You provided a written response to the inspectional findings on January 25, 2024, describing corrective actions taken by your firm. After reviewing the inspectional findings and response that your firm provided, we are issuing this letter to advise you of FDA’s concerns and provide detailed information describing the findings at your facility. We also address your response below.\u003C\u002Fp>\n\n\u003Cp>Your significant violations are as follows:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Supply-Chain Program (21 CFR Part 117, Subpart G)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. You did not implement a risk-based supply-chain program for those raw materials and ingredients for which you have identified a hazard requiring a supply-chain-applied control, as required per 21 CFR 117.405(a)(1). Specifically, your written supply-chain program does not provide assurance that a hazard requiring a supply-chain-applied control has been significantly minimized or prevented, as required per 21 CFR 117.410(c). You receive untreated herbs, spices, dried fruits and peels, and dried vegetable products. You direct the untreated products to \u003Cstrong>(b)(4)\u003C\u002Fstrong> third-party providers that apply&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. You stated during the inspection that you manage your third-party \u003Cstrong>(b)(4)\u003C\u002Fstrong> providers through your supply-chain program, and you expect \u003Cstrong>(b)(4)\u003C\u002Fstrong> providers to treat your products with validated parameters that will provide a \u003Cstrong>(b)(4)\u003C\u002Fstrong> reduction for \u003Cem>Salmonella\u003C\u002Fem>. Per your Hazard Analysis &amp; Preventive Controls Determination record at step “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” the preventive control measure is “Validated lethality ‘kill step’ with Treatment Certificate”. However, your supply-chain program does not verify that the parameters selected and applied by your \u003Cstrong>(b)(4)\u003C\u002Fstrong> providers are adequate to control the hazard of vegetative pathogens such as \u003Cem>Salmonella\u003C\u002Fem>. You do not review the process parameters identified in the treatment certificate from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> providers, as identified as a preventive control measure required by your Hazard Analysis, and you have not comprehensively evaluated whether the parameters are appropriate for all your products undergoing the treatment. You do not maintain documentation that the untreated spices you purchase and send to the third-party \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;providers are treated under a validated process that delivers an appropriate destruction of \u003Cem>Salmonella\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>As examples:\u003C\u002Fp>\n\n\u003Cp>a. On March 30, 2023, you sent \u003Cstrong>(b)(4)\u003C\u002Fstrong> of Organic Caraway Seeds to \u003Cstrong>(b)(4)\u003C\u002Fstrong> for treatment. You received a \u003Cstrong>(b)(4)\u003C\u002Fstrong> Certificate dated April 7, 2023, that stated the caraway seeds were processed at a temperature of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and “[t]he temperature was held for the duration at the core of the product.” You have not verified that this \u003Cstrong>(b)(4)\u003C\u002Fstrong> has been validated to provide an appropriate logarithmic reduction for pathogens such as Salmonella. The third-party audit report for \u003Cstrong>(b)(4)\u003C\u002Fstrong> stated, “treatment validations will occur upon request of the customer”. You have not requested a validation study to support the process parameters listed on the caraway seeds \u003Cstrong>(b)(4)\u003C\u002Fstrong> certificate. Specifically, during the inspection you told our investigator that you have not reviewed validation studies, as they are proprietary to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> providers, and you do not maintain documentation that assures the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process delivers a \u003Cstrong>(b)(4)\u003C\u002Fstrong> reduction. The third-party audit report also stated (under review of the Food Safety Plan at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> step), “No pathogens were identified since this is just a customer treatment (toll processing) with no validation [by HQO]. This is disclosed to service customers vis contracts or WO.” The caraway seeds at issue were used in the processing of O Montreal a.k.a. Nebbraska Stk, lot # 65443. You have four validation studies conducted prior to 2017 for black peppercorn, sliced ginger, parsley and crushed red pepper – all of which listed critical parameters with higher time and\u002For temperatures than what is listed on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> certificate.\u003C\u002Fp>\n\n\u003Cp>In your written response, you stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is working with their technical department to determine the best way to address this concern. However, your response did not demonstrate that all products sent to third-party \u003Cstrong>(b)(4)\u003C\u002Fstrong> providers will be treated with appropriate parameters to control \u003Cem>Salmonella\u003C\u002Fem>. You did not include a revised procedure for your supply-chain program or revised implementation records. You did not indicate that you will ensure the provider validated its treatment, you will review this validation information, or you will verify the validation appropriately applies to each type of product sent to this provider.\u003C\u002Fp>\n\n\u003Cp>Also, you have previously promised to take corrective actions. At the conclusion of the FDA 2020 inspection, an FDA-483 was issued to you on December 4, 2020, for failure to identify a preventive control for pathogens in your RTE dried herbs and spices and for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw materials which you sent to a third-party \u003Cstrong>(b)(4)\u003C\u002Fstrong> facility; you did not verify that validated \u003Cstrong>(b)(4)\u003C\u002Fstrong> processes were in place. You stated in your response, dated December 24, 2020, that all products would be treated with a validated lethality process by either your supplier or contracted third-party facility. You also stated, “Documentation on the validated lethality treatment must be reviewed by HQO prior to shipment of product to ensure that the supplier has a validated lethality treatment for the particular product and size\u002Fshape that is to be shipped for treatment.” This review was not conducted.\u003C\u002Fp>\n\n\u003Cp>b. On September 6, 2023, you sent \u003Cstrong>(b)(4)\u003C\u002Fstrong> of dried Organic Lemon Peel to \u003Cstrong>(b)(4)\u003C\u002Fstrong> for treatment. You received a certificate of treatment that same day that stated the “Minimum Temperature &amp; Dwell Time: \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” The third-party audit report for \u003Cstrong>(b)(4)\u003C\u002Fstrong> stated the critical limit for the treatment is \u003Cstrong>(b)(4)\u003C\u002Fstrong>”, but product and customer specific. You did not verify that this \u003Cstrong>(b)(4)\u003C\u002Fstrong> has been validated to provide an appropriate logarithmic reduction for pathogens such as \u003Cem>Salmonella\u003C\u002Fem> or how it is applicable to each type of product you send for treatment. During the inspection, you told our investigator that you have not reviewed validation studies, as they are proprietary to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> providers, and that you do not maintain documentation that assures the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process delivers a \u003Cstrong>(b)(4)\u003C\u002Fstrong> reduction. The lemon peel was used in the manufacturing of Organic No Salt Blend, lot # 65724.\u003C\u002Fp>\n\n\u003Cp>In your written response, you stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong> revised the language on its treatment certificate to include the statement: “The treatment process follow \u003Cem>[sic]\u003C\u002Fem> our ’\u003Cstrong>(b)(4)\u003C\u002Fstrong>’ by subjecting the product to our \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>of pathogens (Salmonella) that follow specific treatment parameters which are product specific.” However, your response did not demonstrate that all products will be treated with appropriate parameters to control \u003Cem>Salmonella\u003C\u002Fem>. You did not indicate that you will review the validation information relied on by the provider to ensure the treatment is adequate. You did not indicate that you will verify the validation appropriately applies to each type of product sent to this provider.\u003C\u002Fp>\n\n\u003Cp>Also, your written supply chain program procedure entitled “VENDOR MANAGEMENT PROGRAM, Revision Date: 06\u002F12\u002F2023” states, under “Vendor Monitoring”, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” Per the procedure, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to assist with ongoing monitoring to ensure vendor compliance. On December 4, 2023, our investigator requested to review the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> of your suppliers who provided raw materials used in the manufacturing of No Salt Blend. You were unable to provide a \u003Cstrong>(b)(4)\u003C\u002Fstrong> for one of the suppliers. Furthermore, you indicated that you stopped completing \u003Cstrong>(b)(4)\u003C\u002Fstrong> for all your suppliers after June 2021 despite still receiving raw materials from some suppliers since that date. Also, \u003Cstrong>(b)(4)\u003C\u002Fstrong> completed up until then and reviewed during the inspection were incomplete to ensure adequate supply-chain control. For example, the supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> (which supplied Organic Vegmix containing carrot, garlic, onion, red bell pepper, and tomato granules) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> (which supplied organic cumin) dated June 4, 2021 were incomplete in that you did not record what valid documents you had on file, what documents were missing (e.g., current third-party audit results or validation studies), and what requests were pending. These ingredients were used in the processing of No Salt Blend, lot # 65724.\u003C\u002Fp>\n\n\u003Cp>You explained in your written response that the existing \u003Cstrong>(b)(4)\u003C\u002Fstrong> system for documenting supplier reviews was not maintained due to employee attrition and the realignment of resources. Further, you stated a more sustainable revised system to document supplier compliance and performance in your supply-chain is being developed and it will be utilized \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your decision process to maintain or discontinue approval of a supplier. However, you have previously promised to take corrective actions. At the conclusion of the FDA 2021 inspection, the FDA-483 dated September 17, 2021, included an observation that you did not conduct and document appropriate supplier verification activities such as onsite audits for the control of the pathogen and recontamination with environmental pathogens hazards through the supply-chain. \u003Cstrong>(b)(4)\u003C\u002Fstrong> was \u003Cstrong>(b)(4)\u003C\u002Fstrong> suppliers given as an example for this observation. Further, it was noted in the 2021 inspection report that you did not have complete supplier documentation per the Vendor Management Program in place at the time for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In your response received on October 8, 2021, you explained you developed a \u003Cstrong>(b)(4)\u003C\u002Fstrong> system and began a pilot program in April 2021 which you expanded to include all suppliers in October 2021. Further, you promised to implement and maintain this “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” system to ensure maintenance of required records. Your response did not include evidence to demonstrate the system had been implemented per your description of its capabilities. We are concerned that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system may not be attainable as you failed to provide evidence or explanation of how it will be different from your previous \u003Cstrong>(b)(4)\u003C\u002Fstrong> system developed in response to the 2021 Inspection.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Hazard Analysis and Risk-Based Preventive Controls (21 CFR Part 117, Subpart C)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>2. You did not conduct a reanalysis of your food safety plan when needed, as required by 21 CFR 117.170. You must conduct a reanalysis of the food safety plan as a whole, or the applicable portion of the food safety plan, whenever you became aware of new information about potential hazards associated with the food, as required per 21 CFR 117.170(b)(2). Specifically, on April 28, 2023, you became aware of new information when you received a complaint from your customer that Ground Organic Parsley, lot # 62868 and lot # 63196, tested positive for the pesticide Chlorpyrifos (\u003Cstrong>(b)(4)\u003C\u002Fstrong>). There is no tolerance for Chlorpyrifos in parsley; therefore, the parsley lots are adulterated within the meaning of section 402(a)(2)(B) of the Act [21 U.S.C. § 342(a)(2)(B)], in that they bear or contain a pesticide chemical residue that is unsafe within the meaning of section 408(a) of the Act [21 U.S.C. § 346 (a)].\u003C\u002Fp>\n\n\u003Cp>During the inspection, our investigator discussed with you that pesticides was not identified in your hazard analysis as a hazard requiring a supply-chain control. Your hazard analysis includes a justification of “only using organic suppliers with \u003Cstrong>(b)(4)\u003C\u002Fstrong> crop testing for pesticides”. Considering the complaint from April 2023, a reanalysis of the pesticide hazard is warranted to consider whether pesticides are a hazard requiring a supply-chain-applied control.\u003C\u002Fp>\n\n\u003Cp>In your written response you included a statement, in relation to unidentified hazards, that your Food Safety Team will review your current Food Safety Plan and make necessary changes. However, you did not provide evidence of review and revision or a timeframe for review and revision of your Food Safety Plan.\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>We also offer the following comment:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>We note that in your supply-chain procedure “VENDOR MANAGEMENT PROGRAM Revision Date: 06\u002F12\u002F2023”, as a “Minimum Requirement for All Approved Vendors”, you identified a supplier verification activity of an \u003Cstrong>(b)(4)\u003C\u002Fstrong> onsite audit for GMPs and food safety. Furthermore, you stated that copies of third-party audit results are reviewed for passing score, corrective actions to observations, processing procedures, sanitation, traffic flow, GMP programs, and environmental monitoring. However, your written response acknowledged that you do not consistently document your review of third-party audit results. For the supplier verification activity of an onsite audit, you must review the audit results and document that review in order to ensure supply-chain-applied control.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response to this letter should be sent to:\u003C\u002Fp>\n\n\u003Cp>Sergio Chavez, Director, Compliance Branch\u003Cbr>\nFood and Drug Administration\u003Cbr>\nOffice of Human and Animal Foods Division West 5\u003Cbr>\n1201 Harbor Bay Parkway\u003Cbr>\nAlameda, CA 94502\u003C\u002Fp>\n\n\u003Cp>Refer to Unique Identification Number CMS# 677503 when replying.\u003C\u002Fp>\n\n\u003Cp>If you prefer to send your response electronically, please email it to ORAHAFWEST5FirmResponses@fda.hhs.gov. Please include the name of your firm and the Unique Identification number in the title of the e-mail message.\u003C\u002Fp>\n\n\u003Cp>If you have any questions regarding this letter, please contact Kimberly M. Lichter, Compliance Officer, at kimberly.lichter@fda.hhs.gov or (949) 608-2967.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Darla R. Bracy\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations – West Division 5\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Boligala C. Raju\n\nRecipient Title\n\nChief Executive Officer\n\nHigh Quality Organics, Inc.\n\n12101 Moya Blvd.\n\nReno, NV 89506-2600\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West V\n\nUnited States\n\nWARNING LETTER\n\nJuly 8, 2024\n\nWL CMS# 677503\n\nDear Mr. Raju:\n\nThe United States Food and Drug Administration (FDA) inspected your ready-to-eat (RTE) spice facility, located at 12101 Moya Blvd., Reno, NV, from November 27 through December 07, 2023, and January 03 through January 04, 2024. The inspection covered processing and\u002For packaging of RTE organic herbs, spices, dried fruit and peels, and dried vegetables. During our inspection, FDA investigators found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117).\n\nBased on FDA’s inspectional findings, we have determined that the RTE herbs, spices, dried fruit and peels, and dried vegetables processed and\u002For packaged in your facility are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)] in that they have been prepared, packed or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP & PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about the CGMP & PC rule through links on FDA’s homepage at www.fda.gov.\n\nAt the conclusion of the inspection, FDA investigators issued a Form FDA 483 (FDA-483), Inspectional Observations. You provided a written response to the inspectional findings on January 25, 2024, describing corrective actions taken by your firm. After reviewing the inspectional findings and response that your firm provided, we are issuing this letter to advise you of FDA’s concerns and provide detailed information describing the findings at your facility. We also address your response below.\n\nYour significant violations are as follows:\n\nSupply-Chain Program (21 CFR Part 117, Subpart G)\n\n1. You did not implement a risk-based supply-chain program for those raw materials and ingredients for which you have identified a hazard requiring a supply-chain-applied control, as required per 21 CFR 117.405(a)(1). Specifically, your written supply-chain program does not provide assurance that a hazard requiring a supply-chain-applied control has been significantly minimized or prevented, as required per 21 CFR 117.410(c). You receive untreated herbs, spices, dried fruits and peels, and dried vegetable products. You direct the untreated products to (b)(4) third-party providers that apply (b)(4). You stated during the inspection that you manage your third-party (b)(4) providers through your supply-chain program, and you expect (b)(4) providers to treat your products with validated parameters that will provide a (b)(4) reduction for Salmonella. Per your Hazard Analysis & Preventive Controls Determination record at step “(b)(4),” the preventive control measure is “Validated lethality ‘kill step’ with Treatment Certificate”. However, your supply-chain program does not verify that the parameters selected and applied by your (b)(4) providers are adequate to control the hazard of vegetative pathogens such as Salmonella. You do not review the process parameters identified in the treatment certificate from the (b)(4) providers, as identified as a preventive control measure required by your Hazard Analysis, and you have not comprehensively evaluated whether the parameters are appropriate for all your products undergoing the treatment. You do not maintain documentation that the untreated spices you purchase and send to the third-party (b)(4) providers are treated under a validated process that delivers an appropriate destruction of Salmonella.\n\nAs examples:\n\na. On March 30, 2023, you sent (b)(4) of Organic Caraway Seeds to (b)(4) for treatment. You received a (b)(4) Certificate dated April 7, 2023, that stated the caraway seeds were processed at a temperature of (b)(4) and “[t]he temperature was held for the duration at the core of the product.” You have not verified that this (b)(4) has been validated to provide an appropriate logarithmic reduction for pathogens such as Salmonella. The third-party audit report for (b)(4) stated, “treatment validations will occur upon request of the customer”. You have not requested a validation study to support the process parameters listed on the caraway seeds (b)(4) certificate. Specifically, during the inspection you told our investigator that you have not reviewed validation studies, as they are proprietary to the (b)(4) providers, and you do not maintain documentation that assures the (b)(4) process delivers a (b)(4) reduction. The third-party audit report also stated (under review of the Food Safety Plan at the (b)(4) step), “No pathogens were identified since this is just a customer treatment (toll processing) with no validation [by HQO]. This is disclosed to service customers vis contracts or WO.” The caraway seeds at issue were used in the processing of O Montreal a.k.a. Nebbraska Stk, lot # 65443. You have four validation studies conducted prior to 2017 for black peppercorn, sliced ginger, parsley and crushed red pepper – all of which listed critical parameters with higher time and\u002For temperatures than what is listed on the (b)(4) certificate.\n\nIn your written response, you stated that (b)(4) is working with their technical department to determine the best way to address this concern. However, your response did not demonstrate that all products sent to third-party (b)(4) providers will be treated with appropriate parameters to control Salmonella. You did not include a revised procedure for your supply-chain program or revised implementation records. You did not indicate that you will ensure the provider validated its treatment, you will review this validation information, or you will verify the validation appropriately applies to each type of product sent to this provider.\n\nAlso, you have previously promised to take corrective actions. At the conclusion of the FDA 2020 inspection, an FDA-483 was issued to you on December 4, 2020, for failure to identify a preventive control for pathogens in your RTE dried herbs and spices and for the (b)(4) raw materials which you sent to a third-party (b)(4) facility; you did not verify that validated (b)(4) processes were in place. You stated in your response, dated December 24, 2020, that all products would be treated with a validated lethality process by either your supplier or contracted third-party facility. You also stated, “Documentation on the validated lethality treatment must be reviewed by HQO prior to shipment of product to ensure that the supplier has a validated lethality treatment for the particular product and size\u002Fshape that is to be shipped for treatment.” This review was not conducted.\n\nb. On September 6, 2023, you sent (b)(4) of dried Organic Lemon Peel to (b)(4) for treatment. You received a certificate of treatment that same day that stated the “Minimum Temperature & Dwell Time: (b)(4).” The third-party audit report for (b)(4) stated the critical limit for the treatment is (b)(4)”, but product and customer specific. You did not verify that this (b)(4) has been validated to provide an appropriate logarithmic reduction for pathogens such as Salmonella or how it is applicable to each type of product you send for treatment. During the inspection, you told our investigator that you have not reviewed validation studies, as they are proprietary to the (b)(4) providers, and that you do not maintain documentation that assures the (b)(4) process delivers a (b)(4) reduction. The lemon peel was used in the manufacturing of Organic No Salt Blend, lot # 65724.\n\nIn your written response, you stated that (b)(4) revised the language on its treatment certificate to include the statement: “The treatment process follow [sic] our ’(b)(4)’ by subjecting the product to our (b)(4) of pathogens (Salmonella) that follow specific treatment parameters which are product specific.” However, your response did not demonstrate that all products will be treated with appropriate parameters to control Salmonella. You did not indicate that you will review the validation information relied on by the provider to ensure the treatment is adequate. You did not indicate that you will verify the validation appropriately applies to each type of product sent to this provider.\n\nAlso, your written supply chain program procedure entitled “VENDOR MANAGEMENT PROGRAM, Revision Date: 06\u002F12\u002F2023” states, under “Vendor Monitoring”, “(b)(4).” Per the procedure, “(b)(4)” to assist with ongoing monitoring to ensure vendor compliance. On December 4, 2023, our investigator requested to review the (b)(4) for (b)(4) of your suppliers who provided raw materials used in the manufacturing of No Salt Blend. You were unable to provide a (b)(4) for one of the suppliers. Furthermore, you indicated that you stopped completing (b)(4) for all your suppliers after June 2021 despite still receiving raw materials from some suppliers since that date. Also, (b)(4) completed up until then and reviewed during the inspection were incomplete to ensure adequate supply-chain control. For example, the supplier (b)(4) for (b)(4) (which supplied Organic Vegmix containing carrot, garlic, onion, red bell pepper, and tomato granules) and (b)(4) (which supplied organic cumin) dated June 4, 2021 were incomplete in that you did not record what valid documents you had on file, what documents were missing (e.g., current third-party audit results or validation studies), and what requests were pending. These ingredients were used in the processing of No Salt Blend, lot # 65724.\n\nYou explained in your written response that the existing (b)(4) system for documenting supplier reviews was not maintained due to employee attrition and the realignment of resources. Further, you stated a more sustainable revised system to document supplier compliance and performance in your supply-chain is being developed and it will be utilized (b)(4) in your decision process to maintain or discontinue approval of a supplier. However, you have previously promised to take corrective actions. At the conclusion of the FDA 2021 inspection, the FDA-483 dated September 17, 2021, included an observation that you did not conduct and document appropriate supplier verification activities such as onsite audits for the control of the pathogen and recontamination with environmental pathogens hazards through the supply-chain. (b)(4) was (b)(4) suppliers given as an example for this observation. Further, it was noted in the 2021 inspection report that you did not have complete supplier documentation per the Vendor Management Program in place at the time for (b)(4). In your response received on October 8, 2021, you explained you developed a (b)(4) system and began a pilot program in April 2021 which you expanded to include all suppliers in October 2021. Further, you promised to implement and maintain this “(b)(4)” system to ensure maintenance of required records. Your response did not include evidence to demonstrate the system had been implemented per your description of its capabilities. We are concerned that your (b)(4) system may not be attainable as you failed to provide evidence or explanation of how it will be different from your previous (b)(4) system developed in response to the 2021 Inspection.\n\nHazard Analysis and Risk-Based Preventive Controls (21 CFR Part 117, Subpart C)\n\n2. You did not conduct a reanalysis of your food safety plan when needed, as required by 21 CFR 117.170. You must conduct a reanalysis of the food safety plan as a whole, or the applicable portion of the food safety plan, whenever you became aware of new information about potential hazards associated with the food, as required per 21 CFR 117.170(b)(2). Specifically, on April 28, 2023, you became aware of new information when you received a complaint from your customer that Ground Organic Parsley, lot # 62868 and lot # 63196, tested positive for the pesticide Chlorpyrifos ((b)(4)). There is no tolerance for Chlorpyrifos in parsley; therefore, the parsley lots are adulterated within the meaning of section 402(a)(2)(B) of the Act [21 U.S.C. § 342(a)(2)(B)], in that they bear or contain a pesticide chemical residue that is unsafe within the meaning of section 408(a) of the Act [21 U.S.C. § 346 (a)].\n\nDuring the inspection, our investigator discussed with you that pesticides was not identified in your hazard analysis as a hazard requiring a supply-chain control. Your hazard analysis includes a justification of “only using organic suppliers with (b)(4) crop testing for pesticides”. Considering the complaint from April 2023, a reanalysis of the pesticide hazard is warranted to consider whether pesticides are a hazard requiring a supply-chain-applied control.\n\nIn your written response you included a statement, in relation to unidentified hazards, that your Food Safety Team will review your current Food Safety Plan and make necessary changes. However, you did not provide evidence of review and revision or a timeframe for review and revision of your Food Safety Plan.\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\n\nWe also offer the following comment:\n\nWe note that in your supply-chain procedure “VENDOR MANAGEMENT PROGRAM Revision Date: 06\u002F12\u002F2023”, as a “Minimum Requirement for All Approved Vendors”, you identified a supplier verification activity of an (b)(4) onsite audit for GMPs and food safety. Furthermore, you stated that copies of third-party audit results are reviewed for passing score, corrective actions to observations, processing procedures, sanitation, traffic flow, GMP programs, and environmental monitoring. However, your written response acknowledged that you do not consistently document your review of third-party audit results. For the supplier verification activity of an onsite audit, you must review the audit results and document that review in order to ensure supply-chain-applied control.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response to this letter should be sent to:\n\nSergio Chavez, Director, Compliance Branch\n\nFood and Drug Administration\n\nOffice of Human and Animal Foods Division West 5\n\n1201 Harbor Bay Parkway\n\nAlameda, CA 94502\n\nRefer to Unique Identification Number CMS# 677503 when replying.\n\nIf you prefer to send your response electronically, please email it to ORAHAFWEST5FirmResponses@fda.hhs.gov. Please include the name of your firm and the Unique Identification number in the title of the e-mail message.\n\nIf you have any questions regarding this letter, please contact Kimberly M. Lichter, Compliance Officer, at kimberly.lichter@fda.hhs.gov or (949) 608-2967.\n\nSincerely,\n\n\u002FS\u002F\n\nDarla R. Bracy\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations – West Division 5","High Quality Organics, Inc.","high-quality-organics-inc-677503-07082024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhigh-quality-organics-inc-677503-07082024","2026-10-26T08:08:54.858284+00:00","2024-08-06","677503","Mr. Boligala C. Raju","2026-08-19T23:54:29.897+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2024-07-08",{"id":100,"raw":101,"subject":106,"body_html":107,"body_text":108,"firm_name":109,"letter_id":110,"created_at":46,"fei_number":21,"letter_url":111,"updated_at":112,"action_type":24,"case_status":49,"posted_date":113,"marcs_cms_no":114,"product_type":115,"closeout_date":21,"issuing_office":116,"recipient_name":117,"body_fetched_at":118,"delivery_method":119,"recipient_title":21,"reference_number":21,"action_taken_date":120,"medical_device_id":21,"response_letter_date":21},2213,[102,103,104,105,106,13,13,13],"\u003Ctime datetime=\"2023-02-07T14:20:00Z\">02\u002F07\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-12-13T05:00:00Z\">12\u002F13\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fquality-supplement-manufacturing-inc-637182-12132022\">Quality Supplement Manufacturing, Inc.\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations III ","CGMP\u002FManufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Raymundo Osuna\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President of Operations\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Quality Supplement Manufacturing, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>300 N. Macarthur Blvd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Oklahoma City\u003C\u002Fspan>, \u003Cspan>OK\u003C\u002Fspan> \u003Cspan>73127\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations III \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>December 13, 2022\u003Cbr>\n\u003Cbr>\nRE: 637182\u003C\u002Fp>\n\n\u003Cp>Dear Raymundo Osuna,\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 300 N. Macarthur Blvd, Oklahoma City, Oklahoma, from June 7, 2022, through June 13, 2022. Based on inspectional findings and a review of your product labels, we have identified serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on the FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>We received your written response, dated July 5, 2022, to the Form FDA 483, Inspectional Observations, issued to you at the close of the inspection. We have reviewed that document and our comments are listed following each of the significant violations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The inspection of your facility revealed serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). Based on the inspection, we determined that your products, including your&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> products are adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] in that they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\u003C\u002Fp>\n\n\u003Cp>The significant violations documented during the inspection include, but are not limited to the following:\u003C\u002Fp>\n\n\u003Cp>1. You failed to establish product specifications for the identity and purity of the finished batch of the dietary supplement as required by 21 CFR 111.70(e). Specifically, you told our investigator that you have created finished product specifications for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>products; however, these specifications fail to include established specifications for the identity and purity of each of the products.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your response, which states, “Raw materials and finished product shall be tested for identity, purity, or composition as stated in the revised SOP…The Quality Department will be working with the labs to establish specifications for identity, purity, and composition for finished products.” However, we are unable to evaluate the adequacy of your corrective action because you did not provide finished product specifications for our review.\u003C\u002Fp>\n\n\u003Cp>2. You failed to prepare and follow a written master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR 111.205(a). Specifically, you provided MMRs for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also provided batch production records (BPR) for two lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and two lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. With the exception of one lot of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, none of the BPRs matched the MMRs for the products. As such, the BPRs do not support that you are preparing and following written MMRs for each unique formulation and batch size of dietary supplement that you manufacture. In preparing the MMRs, they must include the required elements of 21 CFR 111.210.\u003C\u002Fp>\n\n\u003Cp>We reviewed your response in which you state, “Quality Supplement Manufacturing will have the SOP revised and implement the new process in place within the next 90 days.” We are unable to evaluate the adequacy of your corrective action because you did not provide any MMRs for any manufactured dietary supplement for our review.\u003C\u002Fp>\n\n\u003Cp>3. You failed to verify, for a subset of finished dietary supplement batches that you identify through a sound statistical sampling plan (or for every finished batch), that your finished batch of the dietary supplement meets product specifications for identity, purity, strength, and composition, as required by 21 CFR 111.75(c). Specifically, your firm’s BPRs for the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> (lots \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> (lots \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) indicate that the supplement products contain multiple dietary ingredients; however, during inspection, you stated that you verify the strength for only one dietary ingredient in each of the dietary supplements. Selecting only one of multiple dietary ingredients in the supplement products does not verify your production and process control system is producing a dietary supplement that meets the required product specifications for identity, purity, strength, and composition of the dietary supplement.\u003C\u002Fp>\n\n\u003Cp>We reviewed your response in which you state, “Quality Supplement Manufacturing will have the SOP revised and implement the new process in place within the next 90 days.” We are unable to evaluate the adequacy of your corrective action because you did not provide any standard operating procedures for review.\u003C\u002Fp>\n\n\u003Cp>4. You failed to ensure all tests and examinations that are used to determine whether a specification is met are appropriate and scientifically valid in accordance with 21 CFR 111.75(h)(1). Specifically, you stated “the only analysis for the finished product is by input and a \u003Cstrong>(b)(4)\u003C\u002Fstrong> test.” The input of the various dietary ingredients during production and subsequent analysis of a single dietary ingredient alone in the finished product is not sufficient to verify specifications for identity, purity, strength, and composition in a finished product because inputting specific amounts of various ingredients during manufacturing does not ensure that specifications are met in the finished product, nor does later testing for a single dietary ingredient assess any other components within the finished product.\u003C\u002Fp>\n\n\u003Cp>5. Your quality control personnel did not reject a component and dietary supplement for which a specification was not met, as required by 21 CFR 111.77(a), nor did they approve a treatment, an in-process adjustment, or reprocessing that would ensure the quality of the finished dietary supplement and that the dietary supplement would be packaged and labeled as specified in the MMR. You have in-process specifications within your MMR for fill weights of capsules and tablets to ensure that the finished product meets the label declarations. In several instances, your product neither met these specifications nor were they approved for an appropriate treatment, in-process adjustment, or reprocessing. For example:\u003C\u002Fp>\n\n\u003Cp>&nbsp; o The tablet run sheet for \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>(lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>) includes out of specification fill weights. The BPR states the fill weight range is \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg. The tablet run sheet has weights throughout in the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> range and notes “tablet won’t hit the weight so running \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” A corrective action approved by the firm’s quality unit was not documented.\u003C\u002Fp>\n\n\u003Cp>&nbsp; o The capsule run sheet for \u003Cstrong>(b)(4)\u003C\u002Fstrong> (lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>) includes out of specification fill weights. The BPR states the fill weight range as&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> mg. The QC capsule run sheet has fill weights listed at \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg, \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg, \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg and \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg. There are several notes that adjustments are being made but no corrective action approved by the firm’s quality unit addresses the underweight capsules.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written response in which you state that the root cause for the out of specification fill weights for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product was “lack of training” and that you would be “revising your sample run process” along with “[a] new SOP…to explain the sample run process and how to run deviations.” We are unable to evaluate the adequacy of your corrective action because you did not provide any training records for review, new SOPs, or other documentation on your new sample run or deviation process.\u003C\u002Fp>\n\n\u003Cp>6. Your quality control personnel failed to reject the component, dietary supplement, package, or label, when a specification established in accordance with 21 CFR 111.70 is not met, nor did they approve a permitted treatment, an in-process adjustment, or reprocessing, as required by 21 CFR 111.113(b)(2). For example, your finished product test for your \u003Cstrong>(b)(4)\u003C\u002Fstrong>(lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>) includes strength analysis for the dietary ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The product specification for the ingredient in the supplement products is \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002Ftablet. An out of specification result of \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002Ftablet was reported by your contract lab \u003Cstrong>(b)(4)\u003C\u002Fstrong>. A corrective action approved by the firm’s quality unit was not documented.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written response in which you state that “[the] Quality Department will be signing off on all finished product test results.” We are unable to evaluate the adequacy of your corrective action because you did not provide any test result records or other documentation to show the implementation of the new procedure.\u003C\u002Fp>\n\n\u003Cp>7. Your quality control operations for the MMR, the BPR, and manufacturing operations failed to include approving or rejecting any reprocessing, as required by 21 CFR 111.123(a)(5). For example, \u003Cstrong>(b)(4)\u003C\u002Fstrong> barrels of \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets (lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>) were returned to the blending stage for grinding; however, the BPR does not include documentation showing that your quality control operations approved or rejected any reprocessing.\u003C\u002Fp>\n\n\u003Cp>8. Your quality control failed to document in the BPR at the time of performance the approval and release, or the rejection of a batch of dietary supplement for distribution, as required by 21 CFR 111.260(l)(3). For example, BPRs for&nbsp;&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> (lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) do not include documentation that your quality control personnel approved and released, or rejected, the batches for distribution.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Misbranded Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition, even if your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product was not an unapproved new and misbranded drug, this product and others would be misbranded under section 403 of the Act because it does not comply with the labeling requirements for dietary supplements.\u003Cbr>\nSpecifically, we identified the following:\u003C\u002Fp>\n\n\u003Cp>1. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> dietary supplement products are misbranded under section 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of nutrition information on the labeling for your products does not comply with the labeling requirements for dietary supplements in 21 CFR 101.36. For example,\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Facts label fails to declare the source of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. (21 CFR 101.36(d))\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Facts label incorrectly declares as a (b)(2)-dietary ingredient, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. 21 CFR 101.9(c)(8)(iv) lists an RDI for&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong> mcg based on the AI (adequate intake) that pertains only to&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. \u003Cstrong>(b)(4)\u003C\u002Fstrong> should be listed as a (b)(3)-dietary ingredient.\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product fails to declare the source of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> as indicated in the master manufacturing record; e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> (as \u003Cstrong>(b)(4)\u003C\u002Fstrong>). (21 CFR 101.36(d))\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> fails to express the metric quantitative amounts by weight per serving of other dietary ingredients in accordance with 21 CFR 101.36(b)(3)(ii)(A); for example, \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg should be&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>g.\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> fails to declare the quantitative amount of \u003Cstrong>(b)(4)\u003C\u002Fstrong> with the % Daily Value based upon the presence of \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the product formula, as required by 21 CFR 101.36(b)(2)\u003C\u002Fp>\n\n\u003Cp>2. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product is misbranded within the meaning of section 403(w)(2) of the Act [21 U.S.C. § 343(w)(2)], in that the finished product labels fail to declare the major food allergen, shrimp and crab, as required by section 403(w)(1) of the Act. Specifically, as you have chosen to use a “Contains” statement, you must declare the specific type of Crustacean shellfish.\u003C\u002Fp>\n\n\u003Cp>3. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product and&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> products are each misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that each product label fails to declare the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4. Specifically,\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Your \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Facts label declares the \u003Cstrong>(b)(4)\u003C\u002Fstrong> but fails to state the standardized common name “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” as listed in the reference Herbs of Commerce, as incorporated by 21 CFR 101.4(h).\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product’s ingredient list declares “flavorless coating (Yellow 5, Red 40, Blue 1)” which is not the common or usual name of an ingredient. Furthermore, your batch production records for the product indicate “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” as an ingredient but this ingredient does not appear in the ingredient list of your product label.\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Facts label declares the \u003Cstrong>(b)(4)\u003C\u002Fstrong> but fails to state the standardized common name “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” as listed in Herbs of Commerce. [See 21 CFR 101.4(h)] Furthermore, the source ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong> fails to be listed first within the parentheses, and then followed by the \u003Cstrong>(b)(4)\u003C\u002Fstrong> name within parentheses; for example, \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>4. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product label is misbranded within the meaning of section 403(y) of the Act [21 U.S.C. § 343(y)] in that the label fails to bear a domestic address or domestic phone number through which the responsible person (as described in section 761 of the Act) may receive a report of a serious adverse event with such dietary supplement.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to Dana Lewis, Compliance Officer, U.S. Food and Drug Administration at the following email: dana.lewis@fda.hhs.gov (preferred), or you may mail a hard copy, addressed to Dana Lewis, Compliance Officer, U.S. Food and Drug Administration at 1201 Main Street, Suite 7200, Dallas, TX 75202. If you have any further questions, please contact me at 214-253-5205 or by email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Edmundo Garcia\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food West, Division 3\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Overnight Delivery\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nRaymundo Osuna\n\nRecipient Title\n\nVice President of Operations\n\nQuality Supplement Manufacturing, Inc.\n\n300 N. Macarthur Blvd\n\nOklahoma City, OK 73127\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations III\n\nUnited States\n\nWARNING LETTER\n\nDecember 13, 2022\n\nRE: 637182\n\nDear Raymundo Osuna,\n\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 300 N. Macarthur Blvd, Oklahoma City, Oklahoma, from June 7, 2022, through June 13, 2022. Based on inspectional findings and a review of your product labels, we have identified serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on the FDA’s home page at www.fda.gov.\n\nWe received your written response, dated July 5, 2022, to the Form FDA 483, Inspectional Observations, issued to you at the close of the inspection. We have reviewed that document and our comments are listed following each of the significant violations.\n\nAdulterated Dietary Supplements\n\nThe inspection of your facility revealed serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). Based on the inspection, we determined that your products, including your (b)(4), and (b)(4) products are adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] in that they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\n\nThe significant violations documented during the inspection include, but are not limited to the following:\n\n1. You failed to establish product specifications for the identity and purity of the finished batch of the dietary supplement as required by 21 CFR 111.70(e). Specifically, you told our investigator that you have created finished product specifications for your (b)(4) and (b)(4) products; however, these specifications fail to include established specifications for the identity and purity of each of the products.\n\nWe acknowledge your response, which states, “Raw materials and finished product shall be tested for identity, purity, or composition as stated in the revised SOP…The Quality Department will be working with the labs to establish specifications for identity, purity, and composition for finished products.” However, we are unable to evaluate the adequacy of your corrective action because you did not provide finished product specifications for our review.\n\n2. You failed to prepare and follow a written master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR 111.205(a). Specifically, you provided MMRs for the (b)(4) and (b)(4). You also provided batch production records (BPR) for two lots of (b)(4) and two lots of (b)(4). With the exception of one lot of the (b)(4), none of the BPRs matched the MMRs for the products. As such, the BPRs do not support that you are preparing and following written MMRs for each unique formulation and batch size of dietary supplement that you manufacture. In preparing the MMRs, they must include the required elements of 21 CFR 111.210.\n\nWe reviewed your response in which you state, “Quality Supplement Manufacturing will have the SOP revised and implement the new process in place within the next 90 days.” We are unable to evaluate the adequacy of your corrective action because you did not provide any MMRs for any manufactured dietary supplement for our review.\n\n3. You failed to verify, for a subset of finished dietary supplement batches that you identify through a sound statistical sampling plan (or for every finished batch), that your finished batch of the dietary supplement meets product specifications for identity, purity, strength, and composition, as required by 21 CFR 111.75(c). Specifically, your firm’s BPRs for the (b)(4) (lots (b)(4) and (b)(4)) and (b)(4) (lots (b)(4) and (b)(4)) indicate that the supplement products contain multiple dietary ingredients; however, during inspection, you stated that you verify the strength for only one dietary ingredient in each of the dietary supplements. Selecting only one of multiple dietary ingredients in the supplement products does not verify your production and process control system is producing a dietary supplement that meets the required product specifications for identity, purity, strength, and composition of the dietary supplement.\n\nWe reviewed your response in which you state, “Quality Supplement Manufacturing will have the SOP revised and implement the new process in place within the next 90 days.” We are unable to evaluate the adequacy of your corrective action because you did not provide any standard operating procedures for review.\n\n4. You failed to ensure all tests and examinations that are used to determine whether a specification is met are appropriate and scientifically valid in accordance with 21 CFR 111.75(h)(1). Specifically, you stated “the only analysis for the finished product is by input and a (b)(4) test.” The input of the various dietary ingredients during production and subsequent analysis of a single dietary ingredient alone in the finished product is not sufficient to verify specifications for identity, purity, strength, and composition in a finished product because inputting specific amounts of various ingredients during manufacturing does not ensure that specifications are met in the finished product, nor does later testing for a single dietary ingredient assess any other components within the finished product.\n\n5. Your quality control personnel did not reject a component and dietary supplement for which a specification was not met, as required by 21 CFR 111.77(a), nor did they approve a treatment, an in-process adjustment, or reprocessing that would ensure the quality of the finished dietary supplement and that the dietary supplement would be packaged and labeled as specified in the MMR. You have in-process specifications within your MMR for fill weights of capsules and tablets to ensure that the finished product meets the label declarations. In several instances, your product neither met these specifications nor were they approved for an appropriate treatment, in-process adjustment, or reprocessing. For example:\n\no The tablet run sheet for (b)(4) (lot (b)(4)) includes out of specification fill weights. The BPR states the fill weight range is (b)(4) mg. The tablet run sheet has weights throughout in the (b)(4) range and notes “tablet won’t hit the weight so running (b)(4).” A corrective action approved by the firm’s quality unit was not documented.\n\no The capsule run sheet for (b)(4) (lot (b)(4)) includes out of specification fill weights. The BPR states the fill weight range as (b)(4) mg. The QC capsule run sheet has fill weights listed at (b)(4) mg, (b)(4) mg, (b)(4) mg and (b)(4) mg. There are several notes that adjustments are being made but no corrective action approved by the firm’s quality unit addresses the underweight capsules.\n\nWe have reviewed your written response in which you state that the root cause for the out of specification fill weights for your (b)(4) product was “lack of training” and that you would be “revising your sample run process” along with “[a] new SOP…to explain the sample run process and how to run deviations.” We are unable to evaluate the adequacy of your corrective action because you did not provide any training records for review, new SOPs, or other documentation on your new sample run or deviation process.\n\n6. Your quality control personnel failed to reject the component, dietary supplement, package, or label, when a specification established in accordance with 21 CFR 111.70 is not met, nor did they approve a permitted treatment, an in-process adjustment, or reprocessing, as required by 21 CFR 111.113(b)(2). For example, your finished product test for your (b)(4)(lot (b)(4)) includes strength analysis for the dietary ingredient (b)(4). The product specification for the ingredient in the supplement products is (b)(4) mg\u002Ftablet. An out of specification result of (b)(4) mg\u002Ftablet was reported by your contract lab (b)(4). A corrective action approved by the firm’s quality unit was not documented.\n\nWe have reviewed your written response in which you state that “[the] Quality Department will be signing off on all finished product test results.” We are unable to evaluate the adequacy of your corrective action because you did not provide any test result records or other documentation to show the implementation of the new procedure.\n\n7. Your quality control operations for the MMR, the BPR, and manufacturing operations failed to include approving or rejecting any reprocessing, as required by 21 CFR 111.123(a)(5). For example, (b)(4) barrels of (b)(4) tablets (lot (b)(4)) were returned to the blending stage for grinding; however, the BPR does not include documentation showing that your quality control operations approved or rejected any reprocessing.\n\n8. Your quality control failed to document in the BPR at the time of performance the approval and release, or the rejection of a batch of dietary supplement for distribution, as required by 21 CFR 111.260(l)(3). For example, BPRs for (b)(4) (lot (b)(4) and (b)(4)) do not include documentation that your quality control personnel approved and released, or rejected, the batches for distribution.\n\nMisbranded Dietary Supplements\n\nIn addition, even if your (b)(4) product was not an unapproved new and misbranded drug, this product and others would be misbranded under section 403 of the Act because it does not comply with the labeling requirements for dietary supplements.\n\nSpecifically, we identified the following:\n\n1. Your (b)(4) and (b)(4) dietary supplement products are misbranded under section 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of nutrition information on the labeling for your products does not comply with the labeling requirements for dietary supplements in 21 CFR 101.36. For example,\n\no Your (b)(4) Facts label fails to declare the source of the (b)(4). (21 CFR 101.36(d))\n\no Your (b)(4) Facts label incorrectly declares as a (b)(2)-dietary ingredient, “(b)(4)”. 21 CFR 101.9(c)(8)(iv) lists an RDI for (b)(4) of (b)(4) mcg based on the AI (adequate intake) that pertains only to (b)(4). (b)(4) should be listed as a (b)(3)-dietary ingredient.\n\no Your (b)(4) product fails to declare the source of the (b)(4) as indicated in the master manufacturing record; e.g., (b)(4) (as (b)(4)). (21 CFR 101.36(d))\n\no Your (b)(4) fails to express the metric quantitative amounts by weight per serving of other dietary ingredients in accordance with 21 CFR 101.36(b)(3)(ii)(A); for example, (b)(4) mg should be (b)(4)g.\n\no Your (b)(4) fails to declare the quantitative amount of (b)(4) with the % Daily Value based upon the presence of (b)(4) in the product formula, as required by 21 CFR 101.36(b)(2)\n\n2. Your (b)(4) product is misbranded within the meaning of section 403(w)(2) of the Act [21 U.S.C. § 343(w)(2)], in that the finished product labels fail to declare the major food allergen, shrimp and crab, as required by section 403(w)(1) of the Act. Specifically, as you have chosen to use a “Contains” statement, you must declare the specific type of Crustacean shellfish.\n\n3. Your (b)(4) product and (b)(4) products are each misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that each product label fails to declare the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4. Specifically,\n\no Your (b)(4) Facts label declares the (b)(4) but fails to state the standardized common name “(b)(4)” as listed in the reference Herbs of Commerce, as incorporated by 21 CFR 101.4(h).\n\no Your (b)(4) product’s ingredient list declares “flavorless coating (Yellow 5, Red 40, Blue 1)” which is not the common or usual name of an ingredient. Furthermore, your batch production records for the product indicate “(b)(4)” as an ingredient but this ingredient does not appear in the ingredient list of your product label.\n\no Your (b)(4) Facts label declares the (b)(4) but fails to state the standardized common name “(b)(4)” as listed in Herbs of Commerce. [See 21 CFR 101.4(h)] Furthermore, the source ingredient (b)(4) fails to be listed first within the parentheses, and then followed by the (b)(4) name within parentheses; for example, (b)(4)\n\n4. Your (b)(4) product label is misbranded within the meaning of section 403(y) of the Act [21 U.S.C. § 343(y)] in that the label fails to bear a domestic address or domestic phone number through which the responsible person (as described in section 761 of the Act) may receive a report of a serious adverse event with such dietary supplement.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to Dana Lewis, Compliance Officer, U.S. Food and Drug Administration at the following email: dana.lewis@fda.hhs.gov (preferred), or you may mail a hard copy, addressed to Dana Lewis, Compliance Officer, U.S. Food and Drug Administration at 1201 Main Street, Suite 7200, Dallas, TX 75202. If you have any further questions, please contact me at 214-253-5205 or by email.\n\nSincerely,\n\n\u002FS\u002F\n\nEdmundo Garcia\n\nProgram Division Director\n\nOffice of Human and Animal Food West, Division 3","Quality Supplement Manufacturing, Inc.","quality-supplement-manufacturing-inc-637182-12132022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fquality-supplement-manufacturing-inc-637182-12132022","2026-10-26T08:09:46.151063+00:00","2023-02-07","637182","Dietary Supplements","Division of Pharmaceutical Quality Operations III","Raymundo Osuna","2026-08-20T01:16:25.139+00:00","Via Overnight Delivery","2022-12-13",5,{"510k":123,"classification":124,"enforcement":125,"event":126,"event_backfill":127,"pma":128,"warning_letter":129},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]